Welcome to Sinclair Technologies, LLC
Pioneering diagnostic devices and treatments for earlier detection and better management of ocular disease, improving outcomes for patients worldwide.
For nearly 200 years physicians have been limited in their detection of ocular disease by the reliance on the utilization of vision measured with a chart and examination of the eye performed by the physician with lenses. We have now come to realize that both methods fail to demonstrate the early onset of ocular disease and follow the advance of ocular pathology with therefore only poor improvement in functional vision when treatment is applied far too late in the course of the disease progression. Physicians are in desperate need of devices that will detect ocular disease and functional vision impairment earlier in the course, better assess the impact of treatment, and assist in monitoring for recurrence or progression that may require retreatment. Furthermore, such devices must be tied into a centralized, informative database that provides the physician sequential comparisons over time in order to, not only assist in the screening for disease, but also provide for the individual patient risk prediction for assessing progression as well as the response to treatment. These have been the goals of devices as well as ocular treatments pursued by Sinclair Technologies, LLC.
Diagnostic Devices
Learn more about our innovative diagnostic devices and therapeutic treatments for ocular disease.
Advanced measurement of functional vision under real-world luminance and contrast conditions, beyond traditional chart acuity.
Learn More
Vendor-neutral retinal imaging systems with advanced overlay, registration, and AI-assisted lesion tracking over time.
Learn More
Novel therapeutic approach using erythropoietin glycoprotein for treatment of retinal vascular disease and neuroprotection.
Learn More
Ongoing clinical research in micropulse retinal laser therapy, mucosal inflammation, and advanced diagnostic technologies.
Learn MoreOur Team
Led by experts in ophthalmology, wearable computing, and intellectual property law.
Chief Executive Officer
After graduating from the University of Pennsylvania in biochemistry and attending Cambridge University as a Thouron Scholar in biophysics, he graduated from Harvard Medical School in 1973, followed by ophthalmology training at Massachusetts Eye and Ear Infirmary and a fellowship in vitreoretinal diseases at the University of Wisconsin. He then practiced in full time academic vitreoretinal surgery for 20 years, first at Univ. of Penn and then at Drexel-Hahnemann Medical School where he developed the Department of Ophthalmology as Professor and Chairman. Between 1998 and 2019, he continued in private practice as a vitreoretinal surgeon and served as Adjunct Professor of Ophthalmology at the Drexel-Hahnemann School of Medicine and as Adjunct Professor at the Pennsylvania College of Optometry, Salus University. Dr. Sinclair has taught ophthalmic surgeons around the world through Project Orbis and teaches multiple surgical specialties regarding the enhancement of their vision during all manner of surgical procedures, having developed the first surgical simulator. In ophthalmology, his research continues in the development of many digital devices among which are the laser doppler measurement of retinal blood flow, the measurement of real world functional visual fields, and the development of ophthalmic image management and annotation systems. Dr. Sinclair has received Honor and Senior Achievement Awards from the American Academy of Ophthalmology and the American Society of Retinal Specialists and has published more than 100 original scientific papers and holds nearly a dozen device and drug patents.
Chief Operating Officer
Co-Director of the Georgia Tech Wearable Computing Center with two decades of experience designing and implementing sensor systems for a wide variety of applications, combining embedded hardware with pattern recognition algorithms. Early in his career he developed a pressure-based 3D digitizer based on a translucent silicone rubber, giving robots a sense of touch. When Bluetooth radio integrated circuits became available he repurposed them into motion sensors for an activity recognition system. For data capture on small animals he developed a miniature motion sensor weighing just 2 grams. Further projects included the development of gloves for sign language recognition and passive haptic learning. He has helped develop the CHAT underwater wearable computer for dolphin field research and has prototyped human interfaces. Most of the designs combine embedded hardware with pattern recognition algorithms. Early work in weight shift monitoring of patients in wheelchairs helped reduce the incidence of pressure sores and led to the issuance of a patent. He has been sponsored to explore the next generation of head-mounted wearables interaction techniques. Mr. Presti has been an invited speaker at events sponsored by AT&T, BMW, Thyssen Krupp Elevator, and others.
Chief Financial Officer
Technology consultant, computer system designer, software author, and intellectual property attorney with a unique perspective on innovation as a central pedagogical theme. Former Co-Director of the FPRI Wachman Center Program on Teaching Innovation. Mr. Husick holds a Bachelor of Science degree cum laude in Environmental Chemistry from Muhlenberg College and a Juris Doctor degree from the Washington College of Law, where he also did graduate work in microprocessor systems design. He is a partner in Lipton, Weinberger & Husick, an intellectual property law firm, and serves as an adjunct faculty member at the Johns Hopkins University in the Whiting Graduate School of Engineering. He previously served as Co-Director and Senior Fellow of the Foreign Policy Research Institute's Center for the Study of Terrorism. He is a founder of several entrepreneurial ventures, including Infonautics Inc., PocketDoctor.com, and Cloud Pharmaceuticals, Inc. He serves on the Boards of the Clear Vision Foundation and the American Helicopter Museum and Education Center.
Therapeutics
Novel therapeutic approaches for retinal and ocular surface diseases.
A neuroprotective and anti-inflammatory glycoprotein therapy for retinal vascular disease.
Learn More
Advanced treatment approaches for dry eye syndrome and associated mucosal inflammatory conditions.
Learn MoreClinical Studies
Learn more about our ongoing research initiatives.
Get in Touch
Our team is devoted to providing quality patient care. Reach out with any questions.
Sinclair Technologies, LLC
1934 E. Yalecrest Ave
Salt Lake City, Utah 84108
Monday through Friday
8am – 5pm
Closed daily 12:30 – 2pm for lunch
